Showing results (11-20 of 444) with videos related to

Sort By:
Pageof 45
Alzheimer'S Research & Therapy|April 11, 2025
Long-term surveillance of the anti-amyloid monoclonal antibody lecanemab: rights and duties of pharmacovigilanceMonia Donati, Angela Boccia, Fabrizio De Ponti, et al.
Breast Cancer Research and Treatment|November 5, 2020
Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessmentEmanuel Raschi, Michele Fusaroli, Andrea Ardizzoni, et al.
Drug Safety|March 20, 2010
Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting SystemElisabetta Poluzzi, Emanuel Raschi, Domenico Motola, et al.
Expert Opinion on Pharmacotherapy|October 10, 2018
Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver diseaseEmanuel Raschi, Arianna Mazzotti, Elisabetta Poluzzi, et al.
World Journal of Hepatology|September 19, 2014
Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS databaseEmanuel Raschi, Elisabetta Poluzzi, Ariola Koci, et al.
Frontiers in Pharmacology|December 27, 2021
Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting SystemMichele Fusaroli, Emanuel Raschi, Milo Gatti, et al.
Cancers|April 30, 2021
Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting SystemEmanuel Raschi, Michele Fusaroli, Andrea Ardizzoni, et al.
Diabetes, Obesity & Metabolism|July 14, 2018
Observational research on sodium glucose co-transporter-2 inhibitors: A real breakthrough?Emanuel Raschi, Elisabetta Poluzzi, Gian Paolo Fadini, et al.
European Journal of Preventive Cardiology|August 17, 2021
Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting systemMilo Gatti, Ippazio Cosimo Antonazzo, Igor Diemberger, et al.
British Journal of Clinical Pharmacology|December 17, 2008
Exposure to antibacterial agents with QT liability in 14 European countries: trends over an 8-year periodEmanuel Raschi, Elisabetta Poluzzi, Chiara Zuliani, et al.
Pageof 45